? DUKE CANCER INSTITUTE ADMINISTRATION Duke Cancer Institute Administration (DCI-A) supports the Duke Cancer Institute?s Executive Director, senior leaders, program leaders, shared resource leaders, and members to ensure strong service interactions and communications between all constituents across the research, clinical, education, community engagement and outreach areas. The DCI leadership creates the overall strategic direction and research mission for DCI and the Administration operationalizes their vision. DCI Administration?s mission is to promote all activities including strategic planning, coordinated, transparent and outstanding operations that serve the high-level scientific goals of the DCI. The DCI administration team oversees all research administration, clinical research, financial, human resources, strategic planning, community engagement, outreach, education, communication, philanthropy, informatics and IT operations, training and education of DCI. DCI Administration played a major leadership role in DCI and Disease Focus Group Strategic Planning. Additional accomplishments over this grant period include the reorganization and expansion of the administrative team to improve operations, under the direction of a new Associate Director of Administration. In collaboration with the DCI Deputy Director, administration now includes oversight of the Office of Health Equity and, in collaboration with the AD for Training, the new DCI Office of Cancer Research Career Development. DCI-A also established a new organizational structure for the Clinical Research Unit and its services, study coordination, Quality Assurance, Scientific Protocol Review, Compliance, Safety, Regulatory and Training. DCI was able to grow its cancer research activities with a 44% increase ($16M) of institutional support from Duke Health and School of Medicine to support operational infrastructure, provide funds for recruitment and retention, and provide support for protected academic time for DCI faculty. During the funding period, over $75M in philanthropic support was provided to the DCI by a dedicated Development team, including over $19 million in 2017 alone. In 2017, DCI supported the training, education and fellowship grants by providing an additional $8.1M. DCI provided an average of $776,000 per year to support lectures, seminars and supplementary educational activities. The DCI Administration serves 304 members, 14-shared resources and 8 programs across 34 academic departments within 7 schools, and oversees over 300 non-clinical staff to support the academic mission. DCI-A directly manages over $36.5M in annual operating funds, of which $6.3M is philanthropic funds, directly supporting CCSG research programs, shared resources and the clinical research office. In addition, DCI- A oversees $110M in clinical research contracts, 330,502 sf of research, office and shared resource space.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-47
Application #
10118111
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-01
Project End
2024-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784

Showing the most recent 10 out of 513 publications